✦ LIBER ✦
A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
✍ Scribed by Genovese, Mark C.; Greenwald, Maria; Cho, Chul-Soo; Berman, Alberto; Jin, Ling; Cameron, Gregory S.; Benichou, Olivier; Xie, Li; Braun, Daniel; Berclaz, Pierre-Yves; Banerjee, Subhashis
- Book ID
- 121711841
- Publisher
- Wiley (John Wiley & Sons)
- Year
- 2014
- Tongue
- English
- Weight
- 712 KB
- Volume
- 66
- Category
- Article
- ISSN
- 2326-5191
No coin nor oath required. For personal study only.